Compare ADMA Biologics Inc (ADMA) vs Rivian Automotive, Inc. (RIVN) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Rivian (RIVN) trades at $16.49, down 11.49% amid a 75 million share offering announced July 7, 2026, raising dilution concerns despite recent quarterly EPS beats. The stock shows a bullish technical signal with moving averages supporting upside, but RSI indicates overbought conditions. Revenue grew to $5.39B in 2025, yet net losses persist at -$3.65B, with cash flow negative but improving. Analyst consensus is mixed with a $21.29 price target.

Outlook remains challenged by high cash burn and dilution risks, but cost reductions and DOE loan potential offer long-term growth avenues. Investors face volatility from EV competition and execution hurdles, though institutional buy ratings suggest cautious optimism for profitability milestones.